ES2172595T3 - Compuestos de 1-acil-4-alifatilaminopiperidina. - Google Patents

Compuestos de 1-acil-4-alifatilaminopiperidina.

Info

Publication number
ES2172595T3
ES2172595T3 ES95933394T ES95933394T ES2172595T3 ES 2172595 T3 ES2172595 T3 ES 2172595T3 ES 95933394 T ES95933394 T ES 95933394T ES 95933394 T ES95933394 T ES 95933394T ES 2172595 T3 ES2172595 T3 ES 2172595T3
Authority
ES
Spain
Prior art keywords
alkyl
amino
substituted
alkylene
lower alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95933394T
Other languages
English (en)
Inventor
Silvio Ofner
Siem Jacob Veenstra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2172595T3 publication Critical patent/ES2172595T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

LA INVENCION SE REFIERE A NUEVOS COMPUESTOS DE 1-ACIL-4ALIFATILAMINOPIPERIDINA, DE FORMULA (I), EN LA QUE R{SUB,1} ES UN RADICAL BENZOILO, NAFTOILO, O CICLOALCANOILO, SUSTITUIDO O SIN SUSTITUIR CON ALQUILO INFERIOR, ALCOXI INFERIOR, HALOGENO Y/O TRIFLUOROMETILO; R{SUB,2} ES CICLOALQUILO O UN RADICAL FENILO O NAFTILO, QUE ESTA SUSTITUIDO O NO SUSTITUIDO POR ALQUILO INFERIOR, ALCOXI INFERIOR, HALOGENO, NITRO, CIANO Y/O TRIFLUOROMETILO; R{SUB,3} Y R{SUB,4} UNIDOS, SON ALQUILENO INFERIOR O AZA-, OXA-, O TIA-ALQUILENO INFERIOR; O R{SUB,3} ES ALQUILO INFERIOR, ALCOXI INFERIOR-ALQUILO INFERIOR, DIALQUILAMINO INFERIOR-ALQUILO INFERIOR, O UN RADICAL DE FORMULA -(CH{SUB,2}){SUB,N}-C(=O)-R{SUB,5} (IA); Y R{SUB,4} ES HIDROGENO, ALQUILO INFERIOR, O UN RADICAL DE FORMULA -(CH{SUB,2}){SUB,N}C(=O)-R{SUB,5} (IA); R{SUB,5} ES (I) HIDROGENO, ALQUILO O ALQUILO SUSTITUIDO POR HALOGENO, ALCOXI INFERIOR, AMINO O AMINO SUSTITUIDO POR ALQUILO INFERIOR, AMINO-ALQUILO INFERIOR, NONOO DI-ALQUILAMINOALQUILO INFERIOR, ALCANOILO INFERIOR, ALCOXICARBONILO INFERIOR, O ALQUILENO INFERIOR O AZA-, OXA- O TIA-ALQUILENO INFERIOR, (II) HIDROXILO, CICLOALCOXI, ALCOXI INFERIOR O ALCOXI INFERIOR SUSTITUIDO CON ALCOXI INFERIOR, AMINO O AMINO SUSTITUIDO CON ALQUILO INFERIOR, AMINO-ALQUILO INFERIOR, MONO- O DI-ALQUILAMINO INFERIOR-ALQUILO, ALCANOILO INFERIOR, ALCOXICARBONILO INFERIOR, O ALQUILENO INFERIOR, O AZA-, OXA- O TIA-ALQUILENO INFERIOR, O (III) AMINO O AMINO SUSTITUIDO CON ALQUILO INFERIOR, CICLOALQUILO, AMINO-ALQUILO INFERIOR, MONO- O DI-ALQUILAMINOALQUILO INFERIOR, ALCANOILO INFERIOR, ALCOXICARBONILO INFERIOR O ALQUILENO INFERIOR, O AZA-, OXA- O TIA-ALQUILENO INFERIOR; X{SUB,1} ES METILENO, ETILENO, UN ENLACE DIRECTO, UN GRUPO CARBONILO LIBRE O CETALIZADO, O UN GRUPO HIDROXIMETILENO LIBRE O ETERIFICADO; Y N ES 0 O 1; ASI COMO SUS SALES, PROCEDIMIENTOS DE PREPARACION DE LOS COMPUESTOS DESCRITOS EN LA INVENCION, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN, Y SU UTILIZACION COMO INGREDIENTES FARMACEUTICAMENTE ACTIVOS.
ES95933394T 1994-09-30 1995-09-19 Compuestos de 1-acil-4-alifatilaminopiperidina. Expired - Lifetime ES2172595T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH296694 1994-09-30

Publications (1)

Publication Number Publication Date
ES2172595T3 true ES2172595T3 (es) 2002-10-01

Family

ID=4245651

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95933394T Expired - Lifetime ES2172595T3 (es) 1994-09-30 1995-09-19 Compuestos de 1-acil-4-alifatilaminopiperidina.

Country Status (14)

Country Link
US (1) US5935951A (es)
EP (1) EP0783490B1 (es)
JP (1) JPH10506399A (es)
AT (1) ATE212981T1 (es)
AU (1) AU3607895A (es)
CA (1) CA2198382A1 (es)
DE (1) DE69525355T2 (es)
DK (1) DK0783490T3 (es)
ES (1) ES2172595T3 (es)
FI (1) FI971260A0 (es)
HU (1) HUT77318A (es)
NO (1) NO971383L (es)
PT (1) PT783490E (es)
WO (1) WO1996010562A1 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW475930B (en) * 1995-04-24 2002-02-11 Novartis Ag Novel compound, its use and pharmaceutical composition comprising it
NZ321575A (en) * 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
TW429256B (en) * 1995-12-27 2001-04-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-(benzimidazolyl- and imidazopyridinyl)-piperidine derivatives
TW531537B (en) 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
GB0025354D0 (en) * 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
DE10112198A1 (de) * 2001-03-14 2002-09-19 Gruenenthal Gmbh Substituierte Dimethyl-[1-(1-phenyl-cyclohexyl)-piperidin-3-ylmethyl]-amine
GB0203020D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
EP1472222A1 (en) 2002-02-08 2004-11-03 Glaxo Group Limited Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases
GB0203022D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
NZ552397A (en) 2004-07-15 2011-04-29 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
ATE478075T1 (de) 2005-03-08 2010-09-15 Janssen Pharmaceutica Nv Diazaspiro-ä4,4ü-nonanderivate als neurokinin- (nk1)-antagonisten
WO2006123182A2 (en) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Cyclohexyl sulphones for treatment of cancer
EP1904069B1 (en) 2005-07-15 2018-06-13 Albany Molecular Research, Inc. Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
BRPI0616463A2 (pt) 2005-09-29 2011-06-21 Merck & Co Inc composto, composição farmacêutica, e, uso de um composto
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2060563A4 (en) * 2006-09-08 2010-12-22 Dainippon Sumitomo Pharma Co CYCLIC AMINOALKYLCARBOXAMIDE DERIVATIVE
WO2008039327A2 (en) 2006-09-22 2008-04-03 Merck & Co., Inc. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
AU2008204380B2 (en) 2007-01-10 2013-08-15 Msd Italia S.R.L. Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
EP2145884B1 (en) 2007-04-02 2014-08-06 Msd K.K. Indoledione derivative
US8389553B2 (en) 2007-06-27 2013-03-05 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
JP2011515343A (ja) 2008-03-03 2011-05-19 タイガー ファーマテック チロシンキナーゼ阻害薬
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
EP2413932A4 (en) 2009-04-01 2012-09-19 Merck Sharp & Dohme INHIBITORS OF AKT ACTIVITY
BRPI1007737A2 (pt) * 2009-04-20 2015-09-01 Auspex Pharmaceuticals Llc "composto da fórmula estrutural i, composição farmacêutica, método de tratamento de um distúbio mediano por janus quinase 3, método de preparação de um composto da fórmula estrutural ii, e método de preparação de um composto da fórmula estrutural xii"
KR20120034644A (ko) 2009-05-12 2012-04-12 알바니 몰레큘라 리써치, 인크. 아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도
NZ596104A (en) 2009-05-12 2014-01-31 Albany Molecular Res Inc 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof
KR20120023072A (ko) 2009-05-12 2012-03-12 브리스톨-마이어스 스큅 컴퍼니 （Ｓ）-7-（〔1,2,4〕트리아졸〔1,5-ａ〕피리딘-6-일）-4-（3,4-디클로로페닐）-1,2,3,4-테트라하이드로이소퀴놀린의 결정형 및 이의 용도
BR112012008849A2 (pt) 2009-10-14 2015-09-22 Schering Corp composto, composição farmacêutica, e, uso de um composto
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
JP6043285B2 (ja) 2010-08-02 2016-12-14 サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低分子干渉核酸（ｓｉＮＡ）を用いたカテニン（カドヘリン結合型タンパク質）β１（ＣＴＮＮＢ１）遺伝子発現のＲＮＡ干渉媒介性阻害
HUE044815T2 (hu) 2010-08-17 2019-11-28 Sirna Therapeutics Inc Hepatitisz B vírus (HBV) génexpressziójának RNS-interferencia közvetített gátlása, rövid interferáló nukleinsav (SINS) alkalmazásával
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
WO2012036997A1 (en) 2010-09-16 2012-03-22 Schering Corporation Fused pyrazole derivatives as novel erk inhibitors
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
US20140045847A1 (en) 2011-04-21 2014-02-13 Piramal Enterprises Limited Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
DK2729147T3 (en) 2011-07-04 2017-12-18 Irbm - Science Park S P A NK-1 RECEPTOR ANTAGONISTS FOR TREATMENT OF CORNOVA
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3919620A1 (en) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
US9233979B2 (en) 2012-09-28 2016-01-12 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
BR112015012295A8 (pt) 2012-11-28 2023-03-14 Merck Sharp & Dohme Uso de um inibidor de wee1, e, kit para identificar um paciente com câncer
BR112015013611A2 (pt) 2012-12-20 2017-11-14 Merck Sharp & Dohme composto, e, composição farmacêutica
EP2951180B1 (en) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
RU2020131446A (ru) 2018-02-26 2022-03-28 Оспедале Сан Раффаэле С.Р.Л. Антагонисты nk-1 для применения в лечении глазной боли
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP4117673A1 (en) 2020-03-11 2023-01-18 Ospedale San Raffaele S.r.l. Treatment of stem cell deficiency

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8804104D0 (en) * 1988-02-23 1988-03-23 Glaxo Group Ltd Chemical compounds
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
EP0600952B1 (en) * 1991-08-20 1996-04-17 MERCK SHARP & DOHME LTD. Azacyclic compounds, processes for their preparation and pharmaceutical compositions containing them
WO1995011895A1 (en) * 1993-10-26 1995-05-04 Ciba-Geigy Ag N-benzoyl-4-oxy/thio-2-substituted piperidines as substance-p receptor antagonists

Also Published As

Publication number Publication date
WO1996010562A1 (en) 1996-04-11
NO971383D0 (no) 1997-03-24
JPH10506399A (ja) 1998-06-23
DE69525355D1 (de) 2002-03-21
US5935951A (en) 1999-08-10
HUT77318A (hu) 1998-03-30
EP0783490A1 (en) 1997-07-16
ATE212981T1 (de) 2002-02-15
EP0783490B1 (en) 2002-02-06
FI971260A (fi) 1997-03-26
AU3607895A (en) 1996-04-26
NO971383L (no) 1997-05-14
PT783490E (pt) 2002-06-28
FI971260A0 (fi) 1997-03-26
DK0783490T3 (da) 2002-05-13
MX9702092A (es) 1997-10-31
CA2198382A1 (en) 1996-04-11
DE69525355T2 (de) 2002-09-19

Similar Documents

Publication Publication Date Title
ES2172595T3 (es) Compuestos de 1-acil-4-alifatilaminopiperidina.
DE69310501T2 (de) Chinolylbenzofuran derivate als leukotrien-antagonisten
TW430664B (en) Substituted carboxamidothiazoles, their preparation and pharmaceutical compositions containing them
ES8506001A1 (es) Un procedimiento para preparar compuestos de imidazol fusionados
ES2137998T3 (es) Nuevos derivados de aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que contienen estos compuestos.
EA199900242A1 (ru) Аралкил- и аралкилиден-гетероциклические лактамы и имиды
KR960013370A (ko) 트리글리세리드 과다 방지 조성물
CS621987A2 (en) Coating composition
ATE181731T1 (de) Isothioharnstoff-derivate als no synthase hemmer
MA23639A1 (fr) Derives pyrrocarbazole, leur preparation, les compositions pharmaceutiques les contenant, leur utilisation dans le traitement des tumeurs malignes.
MX9306310A (es) Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
FR2696466B1 (fr) Dérivés de 5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one, leur préparation et les médicaments les contenant.
IT1196423B (it) Benzotiazolin-composti
DE69104475T2 (de) Harnstoffderivate, ihre herstellung und deren enthaltende arzneimittel.
ATE38987T1 (de) Neue 2h-1-benzopyran-2-on-derivate, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten.
EA200000116A1 (ru) Противогрибковые соединения на основе 2,4,4-тризамещенных-1,3-диоксоланов
ES8604958A1 (es) Un procedimiento de obtencion de imidazoquinolinas
BE896635A (fr) Compositions pharmaceutiques analgesiques contenant des 5-phenyl-1,4-benzodiazepines.
DE3166645D1 (en) Dibenzoxazonine, dibenzoxazecine, dibenzoxaazacycloundecane derivatives and their corresponding thia- and aza derivatives, their preparation and pharmaceutical compositions
ATE19629T1 (de) N-substituierte derivate des tetrahydroisophthalimids.
IL106597A0 (en) Androst-4-eno(4,5-b)pyrrole derivatives,their preparation and pharmaceutical compositions containing them
FI882421A (fi) 5-fenyl-1,2,3a,4,5,9b-hexahydro-3h -benz(e)indol, deras framstaellning och anvaendning som laekemedel.
GB1115037A (en) Improvements in or relating to indolylethylamines
TH21838A (th) อนุพันธ์ต่างๆของ 1-ออกโซ-2-(เฟนิลซัลโฟนิล อะมิโน)เพนทิลพิเพอริดีน, การเตรียมสารเหล่านี้ และการใช้สารเหล่านี้เกี่ยวกับการรักษาโรค
GB1085690A (en) Improvements in or relating to disinfecting agents and the preparation thereof

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 783490

Country of ref document: ES